Journal of Clinical Endocrinology & Metabolism, Vol 80, 3528-3531, Copyright © 1995 by Endocrine Society

ARTICLES

High maternal serum chorionic gonadotropin level in Downs' syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts

T Eldar-Geva, A Hochberg, N deGroot and D Weinstein
Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.

A unique product of human placenta is CG. Its concentration in maternal blood rises exponentially until 9-10 weeks' gestation, thereafter, it decreases to about 20% of the maximum, remaining constant from 16-17 until 40 weeks. High second-trimester maternal blood level indicates an increased risk for Downs' Syndrome (DS). This study's aim was to determine whether changes occur in the genetic expression of CG subunits in cultured trisomy-21 trophoblasts compared with various gestational age controls. Second-trimester trisomy-21 trophoblasts secrete 10 times more CG than gestational age-matched controls during the first day in culture: 878 (range, 235-2230) IU/g vs. 87 (range, 20- 150) IU/g (P < 0.05). This high secretion closely resembles quantities secreted by first-trimester normal trophoblasts: 7500 (range, 3,850- 10,000) IU/g. Both subunits' messenger RNA content are substantially increased, CG beta much more than CG alpha, although these genes are not located on chromosome 21. We conclude that at least one cause of high second-trimester maternal blood CG in DS pregnancies is a rise in alpha and beta CG messenger RNA levels in the trophoblast. We propose that at 12-14 weeks, when rapid decrease in maternal blood CG levels can be found, higher than normal values may indicate an increased risk for DS.

This article has been cited by other articles:

				E. K.O. Ng, A. El-Sheikhah, R. W.K. Chiu, K.C. A. Chan, M. Hogg, R. Bindra, T. N. Leung, T. K. Lau, K. H. Nicolaides, and Y.M. D. Lo Evaluation of Human Chorionic Gonadotropin {beta}-Subunit mRNA Concentrations in Maternal Serum in Aneuploid Pregnancies: A Feasibility Study Clin. Chem., June 1, 2004; 50(6): 1055 - 1057. [Full Text] [PDF]

				J.-L. Frendo, J. Guibourdenche, G. Pidoux, M. Vidaud, D. Luton, Y. Giovangrandi, D. Porquet, F. Muller, and D. Evain-Brion Trophoblast Production of a Weakly Bioactive Human Chorionic Gonadotropin in Trisomy 21-Affected Pregnancy J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 727 - 732. [Abstract] [Full Text] [PDF]

				F. M. Reis, D. D'Antona, and F. Petraglia Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy Endocr. Rev., April 1, 2002; 23(2): 230 - 257. [Abstract] [Full Text] [PDF]

				J. L. Frendo, M. Vidaud, J. Guibourdenche, D. Luton, F. Muller, D. Bellet, Y. Giovagrandi, A. Tarrade, D. Porquet, P. Blot, et al. Defect of Villous Cytotrophoblast Differentiation into Syncytiotrophoblast in Down's Syndrome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3700 - 3707. [Abstract] [Full Text]

				E. Jauniaux, S. Bao, A. Eblen, X. Li, Z.M. Lei, S. Meuris, and Ch.V. Rao HCG concentration and receptor gene expression in placental tissue from trisomy 18 and 21 Mol. Hum. Reprod., January 1, 2000; 6(1): 5 - 10. [Abstract] [Full Text] [PDF]

				R. Goshen What factors regulate HCG production in Down's syndrome pregnancies?: Screening for Down's syndrome using HCG concentrations - a common practice but still and enigma Mol. Hum. Reprod., October 1, 1999; 5(10): 893 - 895. [Full Text] [PDF]

				M. Knofler What factors regulate HCG production in Down's syndrome pregnancies?: Regulation of HCG during normal gestation and in pregnancies affected by Down's syndrome Mol. Hum. Reprod., October 1, 1999; 5(10): 895 - 897. [Full Text] [PDF]